SEARCH

SEARCH BY CITATION

References

  • Ambati J, Ambati BK, Yoo SH, Ianchulev S & Adamis AP (2003): Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48: 257293.
  • Arevalo JF, Maia M, Flynn HW Jr et al. (2008): Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92: 213216.
  • Arevalo JF, Sanchez JG, Wu L et al. (2010): Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology 117: 19741981.
  • Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A & Noureddin BN (2009): Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148: 5965.
  • Batman C & Ozdamar Y (2010): The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 41: 190195.
  • Bressler SB (2009): Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116(10 Suppl): S1S7.
  • Chan CK, Meyer CH, Gross JG et al. (2007): Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27: 541551.
  • Chen JT, Chen PL, Chang YH, Chien MW, Chen YH & Lu DW (2006): Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro. Exp Eye Res 83: 10521062.
  • Cordero Coma M, Sobrin L, Onal S, Christen W & Foster CS (2007): Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114: 15741579.
  • Edwards RB (1982): Culture of mammalian retinal pigment epithelium and neural retina. Methods Enzymol 81: 3943.
  • Eibl KH, Banas B, Schoenfeld CL, May CA, Neubauer AS, Priglinger S, Kampik A & Welge-Lussen U (2003): Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 44: 35563561.
  • Forooghian F, Kertes PJ, Eng KT, Agrón E & Chew EY (2010): Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 51: 23882392.
  • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR & VEGF inhibition study in Ocular Neovascularization Clinical Trial Group (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 28052816.
  • Grossniklaus HE & Green WR (1998): Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group. Arch Ophthalmol 116: 745749.
  • Grossniklaus HE, Martinez JA, Brown VB, Lambert HM, Sternberg P Jr, Capone A Jr, Aaberg TM & Lopez PF (1992): Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 114: 464472.
  • He PM, He S, Garner JA, Ryan SJ & Hinton DR (1998): Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor. Biochem Biophys Res Commun 249: 253257.
  • He S, Chen Y, Khankan R et al. (2008): Connective tissue growth factor as a mediator of intraocular fibrosis. Invest Ophthalmol Vis Sci 49: 40784088.
  • Heiduschka P, Fietz H, Hofmeister S et al. (2007): Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 28142823.
  • Hiscott PS, Grierson I & McLeod D (1984): Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study. Br J Ophthalmol 68: 708715.
  • Hiscott P, Morino I, Alexander R, Grierson I & Gregor Z (1989): Cellular components of subretinal membranes in proliferative vitreoretinopathy. Eye 3: 606610.
  • Hiscott P, Sheridan C, Magee RM & Grierson I (1999): Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 18: 167190.
  • Inoki I, Shiomi T, Hashimoto G et al. (2002): Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16: 219221.
  • Kalluri R & Neilson EG (2003): Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 17761784.
  • Kalluri R & Weinberg RA (2009): The basics of epithelial-mesenchymal transition. J Clin Invest 119: 14201428.
  • Klettner A & Roider J (2008): Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49: 45234527.
  • Kon CH, Occleston NL, Aylward GW & Khaw PT (1999): Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 40: 705712.
  • Kuiper EJ, Van Nieuwenhoven FA, de Smet MD et al. (2008): The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 3: e2675.
  • Leask A & Abraham DJ (2003): The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 81: 355363.
  • Li J, Zhang YP & Kirsner RS (2003): Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 60: 107114.
  • Liang CC, Park AY & Guan JL (2007): In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329333.
  • Liou GI, Matragoon S, Samuel S et al. (2002): MAP kinase and beta-catenin signaling in HGF induced RPE migration. Mol Vis 8: 483493.
  • Luo Y, Zhuo Y, Fukuhara M & Rizzolo LJ (2006): Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest Ophthalmol Vis Sci 47: 36443655.
  • Mazure A & Grierson I (1992): In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 33: 34073416.
  • Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN & Venkatraman AS (2005): Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 10351047.
  • Mordenti J, Cuthbertson RA, Ferrara N et al. (1999): Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536544.
  • Nicholson BP & Schachat AP (2010): A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248: 915930.
  • Parapuram SK, Chang B, Li L, Hartung RA, Chalam KV, Nair-Menon JU, Hunt DM & Hunt RC (2009): Differential effects of TGFbeta and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50: 59655974.
  • Ronan SM, Yoganathan P, Chien FY et al. (2007): Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 27: 535540.
  • Rosenfeld PJ, Fung AE & Puliafito CA (2005a): Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36: 336339.
  • Rosenfeld PJ, Moshfeghi AA & Puliafito CA (2005b): Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331335.
  • Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY & MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 14191431.
  • Schlingemann RO (2004): Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242: 91101.
  • Tamiya S, Liu L & Kaplan HJ (2010): Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci 51: 27552763.
  • The Eye Diseases Prevalence Research Group (2004): Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477485.
  • Wang Y, Bian ZM, Yu WZ, Yan Z, Chen WC & Li XX (2010): Induction of interleukin-8 gene expression and protein secretion by C-reactive protein in ARPE-19 cells. Exp Eye Res 91: 135142.
  • Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H & Honda Y (2005): Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina 25: 911918.
  • Werner S & Grose R (2003): Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835870.